Personalis Income from Continuous Operations 2018-2025 | PSNL
Personalis income from continuous operations from 2018 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Personalis Annual Income from Continuous Operations
(Millions of US $) |
| 2024 |
$-81 |
| 2023 |
$-108 |
| 2022 |
$-113 |
| 2021 |
$-65 |
| 2020 |
$-41 |
| 2019 |
$-25 |
| 2018 |
$-20 |
| 2017 |
$-24 |
Personalis Quarterly Income from Continuous Operations
(Millions of US $) |
| 2025-06-30 |
$-20 |
| 2025-03-31 |
$-16 |
| 2024-12-31 |
$-16 |
| 2024-09-30 |
$-39 |
| 2024-06-30 |
$-13 |
| 2024-03-31 |
$-13 |
| 2023-12-31 |
$-27 |
| 2023-09-30 |
$-29 |
| 2023-06-30 |
$-24 |
| 2023-03-31 |
$-29 |
| 2022-12-31 |
$-31 |
| 2022-09-30 |
$-26 |
| 2022-06-30 |
$-28 |
| 2022-03-31 |
$-28 |
| 2021-12-31 |
$-20 |
| 2021-09-30 |
$-18 |
| 2021-06-30 |
$-15 |
| 2021-03-31 |
$-12 |
| 2020-12-31 |
$-13 |
| 2020-09-30 |
$-10 |
| 2020-06-30 |
$-9 |
| 2020-03-31 |
$-9 |
| 2019-12-31 |
$-7 |
| 2019-09-30 |
$-7 |
| 2019-06-30 |
$-6 |
| 2019-03-31 |
$-6 |
| 2018-12-31 |
|
| 2018-09-30 |
$-4 |
| 2018-06-30 |
$-7 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.428B |
$0.085B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
